Clinical Trials

Phase 1 Study of COM701 in Patients
with Advanced Solid Tumors

This study is designed to evaluate the safety, tolerability and preliminary antitumor activity of COM701, an anti-PVRIG antibody, as monotherapy and in combination with nivolumab. An expansion cohort evaluates the preliminary antitumor activity of COM701 monotherapy in patients with certain tumor types such as non-small cell lung (NSCLC), breast, ovarian and endometrial cancer. These tumor types were selected based on preclinical data demonstrating high expression of a potential biomarker (PVRL2) in the tumors. Colorectal cancer has been included based on encouraging preliminary antitumor activity of COM701 monotherapy and in combination with nivolumab in the ongoing Phase 1 study.

Phase 1 Dose Escalation Study of COM902 in Patients with Advanced Malignancies

This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of escalating doses of COM902, an anti-TIGIT antibody, monotherapy in patients with advanced malignancies who have exhausted all available standard therapies.

compugen employees in lab
compugen employee in lab

Phase 1/2 Triple Combination Study of COM701 with Opdivo® (nivolumab) and Anti-TIGIT Antibody BMS-986207 in Patients with Advanced Solid Tumors

This triple combination study is designed to evaluate the simultaneous blockade of three immune checkpoint pathways, PVRIG (COM701), TIGIT (BMS-986207) and PD-1 (nivolumab), in patients with advanced solid tumors who have exhausted all available standard of care therapies, including those that may be refractory or non-responsive to standard-of-care immune checkpoint inhibitors.

Phase 1 Study of BAY 1905254 in Patients with Advanced Solid Tumors

This Bayer sponsored study is designed to evaluate the safety and tolerability of BAY 1905254, an anti-ILDR2 antibody licensed to Bayer by Compugen, in a dose escalation study as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. An expansion study is designed to evaluate the combination of BAY 1905254 with pembrolizumab in head and neck squamous cell carcinoma.

compugen employee in lab with vial

Compassionate Use Policy

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Adipiscing diam donec adipiscing tristique risus. Massa ultricies mi quis hendrerit dolor magna eget. Sagittis purus sit amet volutpat consequat mauris nunc congue. Volutpat odio facilisis mauris sit amet massa vitae tortor.

Scroll to Top